On this page

Gentamicin Sulfate

Prescription ANDA TE AT Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Gentamicin Sulfate
Generic name
Gentamicin Sulfate
Dosage form
Solution
Route
Ophthalmic
Marketing category
ANDA · ANDA
Labeler
Proficient Rx LP
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
4
Packages
4
Data completeness
76% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Gentamicin Sulfate 3 mg/mL 1870650 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Solution
Route of administration
Ophthalmic
Presentations
8

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Aminoglycoside Antibacterial [EPC] EPC All 66 members
Aminoglycosides [CS] CS All 66 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
062196
Application type
ANDA · Abbreviated New Drug Application
Approval date
July 2, 1980
Sponsor
SANDOZ
Products on application
1
Submissions recorded
15
Products approved under application 062196.
Product Trade name Form Strength Ingredient Status TE Flags
062196-001 GENTAMICIN SULFATE SOLUTION/DROPS GENTAMICIN SULFATE Prescription AT RS

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
No
Reference Standard
Yes

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 062196.
Type No. Action Status Date Review
Supplement 15 Manufacturing (CMC) Approved December 23, 2002 —
Supplement 14 Manufacturing (CMC) Approved November 17, 2000 —
Supplement 13 Manufacturing (CMC) Approved September 12, 2000 —
Supplement 11 Manufacturing (CMC) Approved April 28, 2000 —
Supplement 12 Manufacturing (CMC) Approved April 7, 2000 —
Supplement 10 Manufacturing (CMC) Approved May 7, 1999 —
Supplement 5 Labeling Approved September 18, 1998 —
Supplement 8 Manufacturing (CMC) Approved April 3, 1998 —
Supplement 7 Manufacturing (CMC) Approved July 29, 1997 —
Supplement 6 Manufacturing (CMC) Approved July 29, 1997 —
Supplement 4 Manufacturing (CMC) Approved June 9, 1997 —
Supplement 3 Manufacturing (CMC) Approved December 9, 1996 —
Supplement 2 Manufacturing (CMC) Approved July 12, 1996 —
Supplement 1 Manufacturing (CMC) Approved December 28, 1995 —
Original application 1 Approved July 2, 1980 —

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20250501). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20250501 HUMAN PRESCRIPTION DRUG · 20240102

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE: Gentamicin Sulfate Ophthalmic Solution is indicated in the topical treatment of ocular bacterial infections, including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis, and dacryocystitis caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION : Instill one or two drops into the affected eye(s) every four hours. In severe infections, dosage may be increased to as much as two drops once every hour.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS: Gentamicin Sulfate Ophthalmic Solution is contraindicated in patients with known hypersensitivity to any of the components.

WARNINGS: NOT FOR INJECTION INTO THE EYE. Gentamicin Sulfate Ophthalmic Solution is not for injection. It should never be injected subconjunctivally, nor should it be directly introduced into the anterior chamber of the eye.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS Bacterial and fungal corneal ulcers have developed during treatment with gentamicin ophthalmic preparations. The most frequently reported adverse reactions are ocular burning and irritation upon drug instillation, non-specific conjunctivitis, conjunctival epithelial defects, and conjunctival hyperemia. Other adverse reactions which have occurred rarely are allergic reactions, thrombocytopenic purpura, and hallucinations. To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Description

openFDA Drug Labeling

DESCRIPTION Gentamicin Sulfate is a water-soluble antibiotic of the aminoglycoside group. Gentamicin Sulfate Ophthalmic Solution is a sterile, aqueous solution buffered to approximately pH 7 for ophthalmic use. Gentamicin is obtained from cultures of Micromonospora purpurea . It is a mixture of the sulfate salts of gentamicin C 1 , C 2 , and C 1A . All three components appear to have similar antimicrobial activities. Gentamicin sulfate occurs as white powder and is soluble in water and insoluble in alcohol. The structure is as follows: Established name: Gentamicin Sulfate Chemical name: 0-3-Deoxy-4-C-methyl-3-(methylamino)-β-L-arabinopyranosyl-(1→6)-0-[2,6-diamino-2,3,4,6-tetradeoxy-α-D-erythro-hexopyranosyl-(1→4)]-2-deoxy-D-streptamine. Ingredients: Each mL contains: Active: Gentamicin Sulfate USP (equivalent to 3 mg gentamicin). Preservative: Benzalkonium Chloride 0.1 mg (0.01%). Inactives: Dibasic Sodium Phosphate Anhydrous, Sodium Chloride, Sodium Hydroxide and/or Hydrochloric Acid (to adjust pH), Tyloxapol and Purified Water. chemicalstructure

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED: Gentamicin Sulfate Ophthalmic Solution: 5 mL in plastic DROP-TAINER * dispenser. NDC 71205-333-05 STORAGE: Protect from light and store away from heat. Store at controlled room temperature 15°-25°C (59°-77°F). To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc., at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. *DROP-TAINER is a registered trademark of Alcon Research, Ltd. Rx Only

Adverse event reports

Source: openFDA FAERS
15,708
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: GENTAMICIN SULFATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
76420-137-05 76420-137 Asclemed USA, Inc. 5 mL in 1 BOTTLE, PLASTIC (76420-137-05) March 4, 2022
68071-4775-5 68071-4775 NuCare Pharmaceuticals,Inc. 5 mL in 1 BOTTLE (68071-4775-5) February 20, 2019
71205-333-05 71205-333 Proficient Rx LP 5 mL in 1 BOTTLE, PLASTIC (71205-333-05) September 1, 2019
61314-633-05 61314-633 Sandoz Inc 1 BOTTLE, DROPPER in 1 CARTON (61314-633-05) / 5 mL in 1 BOTTLE, DROPPER April 5, 1996
76420-137 76420-137 Asclemed USA, Inc. — April 5, 1996
68071-4775 68071-4775 NuCare Pharmaceuticals,Inc. — April 5, 1996
71205-333 71205-333 Proficient Rx LP — April 5, 1996
61314-633 61314-633 Sandoz Inc — April 5, 1996

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.